132 related articles for article (PubMed ID: 35378410)
1. Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.
Guiard E; Baldini C; Pobel C; Assi T; Bernard-Tessier A; Martin-Romano P; Hollebecque A; Verlingue L; Geraud A; Michot JM; Armand JP; Soria JC; Massard C; Ammari S
Eur J Cancer; 2022 May; 167():42-53. PubMed ID: 35378410
[TBL] [Abstract][Full Text] [Related]
2. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
3. Patterns of progression in patients treated for immuno-oncology antibodies combination.
Bernard-Tessier A; Baldini C; Castanon E; Martin P; Champiat S; Hollebecque A; Postel-Vinay S; Varga A; Bahleda R; Gazzah A; Michot JM; Ribrag V; Armand JP; Marabelle A; Soria JC; Massard C; Ammari S
Cancer Immunol Immunother; 2021 Jan; 70(1):221-232. PubMed ID: 32700090
[TBL] [Abstract][Full Text] [Related]
4. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types.
Martin-Romano P; Castanon E; Ammari S; Champiat S; Hollebecque A; Postel-Vinay S; Baldini C; Varga A; Michot JM; Vuagnat P; Marabelle A; Soria JC; Ferté C; Massard C
Cancer Med; 2020 Apr; 9(8):2643-2652. PubMed ID: 32074405
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis.
Haaker L; Baldewijns M; De Wever L; Albersen M; Debruyne PR; Wynendaele W; De Meerleer G; Beuselinck B
Clin Genitourin Cancer; 2023 Aug; 21(4):442-451. PubMed ID: 36997468
[TBL] [Abstract][Full Text] [Related]
6. Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors.
Mönch S; Heimer MM; Winkelmann M; Guertler A; Schlaak M; Tufman A; Ben Khaled N; de Toni E; Westphalen CB; von Bergwelt-Baildon M; Dinkel J; Kazmierczak PM; Ingrisch M; Mansour N; Unterrainer M; Heinzerling L; Ricke J; Kunz WG
Cancer Imaging; 2023 Jun; 23(1):58. PubMed ID: 37291665
[TBL] [Abstract][Full Text] [Related]
7. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
8. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
9. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
10. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Xu Z; Li T; Hu X; Hao X; Xing P; Li J
Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
14. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
16. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
19. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
[TBL] [Abstract][Full Text] [Related]
20. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
